Initiating Mounjaro in Type 2 Diabetes Management

Initial Treatment Framework

• The American Diabetes Association recommends metformin as first-line therapy for newly diagnosed type 2 diabetes, unless contraindicated, and should be started at diagnosis with lifestyle modifications 1, 2
• Tirzepatide is not a first-line agent for new-onset diabetes; it should be added when initial therapy proves inadequate 1, 3
• Treatment intensification should not be delayed beyond 3 months if glycemic goals are not met with current therapy 1, 3

Specific Clinical Scenarios for Starting Tirzepatide

• For patients with established cardiovascular disease, guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit as part of the glucose-lowering regimen independent of A1C 1, 3
• In patients with chronic kidney disease, consider agents with renal protective effects when intensifying therapy 4, 5

Priority Populations for Earlier Consideration

• The American College of Cardiology suggests that patients with established cardiovascular disease may benefit from earlier consideration of tirzepatide due to its potential cardiometabolic benefits 1, 3
• Patients with chronic kidney disease may benefit from tirzepatide due to its potential renal protective effects 4, 5

Important Monitoring Considerations

• Assess A1C every 3 months after initiating or intensifying therapy 1, 3, 2
• Reduce insulin or sulfonylurea doses by 20-50% when adding tirzepatide to prevent hypoglycemia 6
• Monitor for gastrointestinal symptoms, which typically diminish over time with continued treatment 7, 8